Maze Therapeutics is a technology company.
Maze Therapeutics has raised $500.0M across 3 funding rounds.
Maze Therapeutics has raised $500.0M in total across 3 funding rounds.
Maze Therapeutics has raised $500.0M in total across 3 funding rounds.
Maze Therapeutics's investors include ARCH Venture Partners, Frazier Healthcare Partners, Matrix Capital Management Company, SignalFire, Third Rock Ventures, Andreessen Horowitz, Canaan Partners.
Maze Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule precision medicines by harnessing human genetics, primarily targeting renal, cardiovascular, and related metabolic diseases like chronic kidney disease (CKD) and obesity.[1][2] It serves patients with genetically driven conditions through its Compass platform, which identifies genetic variants, links them to disease pathways (via "variant functionalization"), and advances targeted therapies; the pipeline is led by wholly owned programs MZE829 (for APOL1 kidney disease) and MZE782 (for CKD), with positive Phase 1 data reported for MZE829 in healthy volunteers.[1][2] Based in South San Francisco with ~121 employees and $496M in total funding (including a $115M recent round), Maze demonstrates strong growth momentum in precision medicine.[2]
Maze Therapeutics emerged from advancements in human genetics to address unmet needs in common diseases like CKD, though specific founding year and founders are not detailed in available sources.[1][3] The company has rapidly progressed to clinical stage, with three programs in trials and others in development, building early traction through its Compass platform and significant venture funding totaling $496M across three rounds.[2][4] Pivotal moments include reporting positive first-in-human Phase 1 results for MZE829, validating its approach to APOL1-mediated kidney disease.[2]
Maze rides the precision medicine trend fueled by genetic sequencing advances, timing perfectly with rising demand for targeted therapies in chronic conditions like CKD affecting millions, where traditional treatments fall short.[1][3] Market forces favoring it include exploding interest in genetics-informed drugs (e.g., APOL1 inhibitors), obesity epidemics, and biopharma's shift to small molecules over biologics for scalability.[2] Maze influences the ecosystem by validating human genetics platforms, potentially accelerating similar ventures and drawing investment to renal/metabolic biotech.
Maze is poised for Phase 2 trials with MZE829 and MZE782, likely expanding its pipeline amid genetics tech maturation and AI-driven variant analysis trends.[2][4] Evolving regulatory support for precision meds and partnerships could amplify its role, positioning it as a leader in genetically stratified renal therapies—transforming patient outcomes from its genetics-first foundation.
Maze Therapeutics has raised $500.0M across 3 funding rounds. Most recently, it raised $120.0M Series D in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $120.0M Series D | ARCH Venture Partners, Frazier Healthcare Partners, Matrix Capital Management Company, SignalFire, Third Rock Ventures | |
| Jan 1, 2022 | $190.0M Venture Round | Andreessen Horowitz, ARCH Venture Partners, Frazier Healthcare Partners, Matrix Capital Management Company, SignalFire, Third Rock Ventures | |
| Feb 1, 2019 | $190.0M Series A | Canaan Partners, Third Rock Ventures |